SECURITIES AND EXCHANGE COMMISSION Conformed
Washington, D.C. 20549 Copy
FORM 10-Q/A
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the quarterly period ended September 30, 1998
------------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the transition period from to
------------- ------------
Commission file number 333-02015
---------
CYTOGEN Corporation
(Exact name of Registrant as specified in its charter)
Delaware 22-2322400
- ------------------------------- -----------------------
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification Number)
600 College Road East, CN 5308, Princeton, NJ 08540-5308
--------------------------------------------------------
(Address of Principal Executive Offices and Zip Code)
Registrant's telephone number, including area code (609) 987-8200
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days: Yes X No .
Indicate the number of shares outstanding of each of the
issuer's classes of common stock, as of the latest practicable
date:
Class Outstanding at October 26, 1998
- ----------------------------- -------------------------------
Common Stock, $.01 par value 58,604,950
PART II - OTHER INFORMATION
Item 6 - Exhibits and Reports on Form 8-K
(a) Exhibits:
1. Amended and Restated Rights Agreement, dated as of
October 19, 1998 between CYTOGEN Corporation and Chase
Mellon Shareholder Services, L.L.C., as Rights Agent.
The Amended and Restated Rights Agreement includes the
Form of Certificate of Designations of Series C Junior
Preferred Stock as Exhibit A, the form of Rights
Certificate as Exhibit B and the Summary of Rights as
Exhibit C. Filed herewith.
10.1 Employment agreement effective as of August 20,
1998 between CYTOGEN Corporation and H. Joseph
Reiser. Filed herewith.
10.2 Loan and Security Agreement, dated as of October
19, 1998 between CYTOGEN Corporation and the CIT
Group/Credit Finance, Inc. Filed herewith.
10.3 Private Equity Line Agreement by and between
Kingsbridge Capital Limited and CYTOGEN Corporation
dated as of October 23, 1998. Filed herewith.
10.4 License Agreement by and between Berlex Laboratories, Inc.
and CYTOGEN Corporation dated as of October 28, 1998.
Filed herewith.
10.5 Addendum to the Letter Agreement effective as of
October 29, 1998 between CYTOGEN Corporation and
DuPont Pharmaceuticals Company. Filed herewith.
27 Financial Data Schedule (Submitted to SEC only in
electronic format).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
CYTOGEN CORPORATION
Date December 30, 1998 By /s/ Jane M. Maida
----------------- ------------------
Jane M. Maida
Chief Accounting Officer
(Authorized Accounting Officer)